Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: A radiation recall dermatitis?

European Journal of Dermatology

Volumn 23, Issue 4, 2013, Pages 544-545

  Reigneau, Marie ^a   Granel Brocard, Florence ^a   Geoffrois, Lionnel ^a   Bauman, Anne Sophie ^a   Tréchot, Philippe ^a   Barbaud, Annick ^a   Schmutz, Jean Luc ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; RETINOIC ACID; VEMURAFENIB;

ADULT; BRAIN METASTASIS; BRAIN RADIATION; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EDEMA; ERYTHEMA; FOREHEAD; HUMAN; HUMAN TISSUE; INTRACRANIAL HYPERTENSION; LETTER; MALE; MELANOMA; RADIATION DERMATITIS; REMISSION; SCALP; SCALP CYST; SKIN CYST; SKIN INDURATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CYSTS; DOSE FRACTIONATION; FOREHEAD; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; RADIODERMATITIS; SCALP; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84884386351     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2108     Document Type: Letter

References (10)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
2. Sosman JA, Kim KB, Schuchter LG, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-714.
3. Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987-994.
4. Boussemart L, Boivin C, Claveau J, et al. Vemurafenib and radiosen-sitization. JAMA Dermatology 2013,in press.
5. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 2012; 148:628-633.
6. Boyd KP, Vincent B, Andea A, Conry RM, Hughey LC. Non-malignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 2012; 67: 1375-1379.
7. Camidge R, Price A. Radiation recall dermatitis may represent the Koebner phenomenon. J Clin Oncol. 2002; 20: 4130, author reply 4130.
8. Ben-Yosef R, Soyfer V, Vexler A. Radiation therapy in cancer patients with psoriasis. The fractioned daily dose and the Koebner phenomen. Radiother Oncol 2005; 74: 21-23.
9. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011; 3: 394-399.
10. Cheepala SB, Yin W, Syed Z, et al. Identification of the B- Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer 2009; 8: 27.